StreetInsider.com News Articles

Form SCHEDULE 13G/A AYTU BIOPHARMA, INC Filed by: LYTTON LAURENCE W

Tue, 17 Feb 2026 13:32:00 -0500

si-local-file:///var/storage/secattach/20260217/26010708.html

Form SCHEDULE 13G/A AYTU BIOPHARMA, INC Filed by: LYTTON LAURENCE W

Tue, 17 Feb 2026 13:32:00 -0500

si-local-file:///var/storage/secattach/20260217/26010708.html

Form SCHEDULE 13G/A AYTU BIOPHARMA, INC Filed by: AWM Investment Company, Inc.

Fri, 13 Feb 2026 14:36:00 -0500

si-local-file:///var/storage/secattach/20260213/25998900.html

Form SCHEDULE 13G/A AYTU BIOPHARMA, INC Filed by: AWM Investment Company, Inc.

Fri, 13 Feb 2026 14:36:00 -0500

si-local-file:///var/storage/secattach/20260213/25998900.html

Aytu BioScience (AYTU) Misses Q2 EPS by 105c

Tue, 03 Feb 2026 16:27:46 -0500

Aytu BioScience (NASDAQ: AYTU) reported Q2 EPS of ($1.05), $1.05 worse than the analyst estimate of $0.00. Revenue for the quarter came in at $15.2 million.

For earnings history and earnings-related data on Aytu BioScience (AYTU) click here.

Form 10-Q AYTU BIOPHARMA, INC For: Dec 31

Tue, 03 Feb 2026 16:08:00 -0500

si-local-file:///var/storage/secattach/20260203/25938726.html

Form 10-Q AYTU BIOPHARMA, INC For: Dec 31

Tue, 03 Feb 2026 16:08:00 -0500

si-local-file:///var/storage/secattach/20260203/25938726.html

Form 8-K AYTU BIOPHARMA, INC For: Feb 03

Tue, 03 Feb 2026 16:06:00 -0500

si-local-file:///var/storage/secattach/20260203/25938625.html

Form 8-K AYTU BIOPHARMA, INC For: Feb 03

Tue, 03 Feb 2026 16:06:00 -0500

si-local-file:///var/storage/secattach/20260203/25938625.html

Aytu BioPharma Reports Fiscal 2026 Second Quarter Operational and Financial Results

Tue, 03 Feb 2026 16:05:00 -0500

Total net revenue of $15.2 million

Adjusted EBITDA¹ of $(0.8) million, which includes EXXUA launch investments

$30.0 million cash balance at December 31, 2025

Company launched EXXUA^™ (gepirone) extended-release tablets ("EXXUA") in December 2025 as the centerpiece of its commercial efforts as it enters the over $22 billion United States prescription major depressive disorder ("MDD") market

Company to host conference call and webcast today, February 3, 2026, at 4:30 p.m. Eastern time

DENVER, CO / ACCESS Newswire / February 3, 2026 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on advancing innovative

Aytu BioPharma Reports Fiscal 2026 Second Quarter Operational and Financial Results

Tue, 03 Feb 2026 16:05:00 -0500

Total net revenue of $15.2 million

Adjusted EBITDA¹ of $(0.8) million, which includes EXXUA launch investments

$30.0 million cash balance at December 31, 2025

Company to host conference call and webcast today, February 3, 2026, at 4:30 p.m. Eastern time

DENVER, CO / ACCESS Newswire / February 3, 2026 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on advancing innovative

Aytu BioPharma to Report Fiscal 2026 Second Quarter Operational and Financial Results on February 3, 2026

Tue, 27 Jan 2026 16:05:00 -0500

DENVER, CO / ACCESS Newswire / January 27, 2026 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases to improve the quality of life for patients, will report its operational and financial results for its second quarter of fiscal 2026, after the market close on Tuesday, February 3, 2026. The Company has scheduled a conference call and webcast that same day, Tuesday, February 3, 2026, at 4:30 p.m. Eastern time, to review the results followed by a question

Aytu BioPharma to Report Fiscal 2026 Second Quarter Operational and Financial Results on February 3, 2026

Tue, 27 Jan 2026 16:05:00 -0500

Form 8-K AYTU BIOPHARMA, INC For: Jan 20

Tue, 20 Jan 2026 16:06:00 -0500

si-local-file:///var/storage/secattach/20260120/25868172.html

Form 8-K AYTU BIOPHARMA, INC For: Jan 20

Tue, 20 Jan 2026 16:06:00 -0500

si-local-file:///var/storage/secattach/20260120/25868172.html

Aytu BioPharma Recaps Investor Day Held on January 20, 2026

Tue, 20 Jan 2026 16:05:00 -0500

DENVER, CO / ACCESS Newswire / January 20, 2026 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases to improve the quality of life for patients, today provided a summary of the Company's Investor Day, held today, Tuesday, January 20, 2026, at 11:00 a.m. Eastern time in New York City. The Investor Day was conducted both in-person and via webcast.

A replay of the event can be found on the Investors section of the Company's website at

Aytu BioPharma Recaps Investor Day Held on January 20, 2026

Tue, 20 Jan 2026 16:05:00 -0500

DENVER, CO / ACCESS Newswire / January 20, 2026 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases to improve the quality of life for patients, today provided a summary of the Company's Investor Day, held today, Tuesday, January 20, 2026, at 11:00 a.m. Eastern time in New York City. The Investor Day was conducted both in-person and via webcast.

A replay of the event can be found on the Investors section of the Company's website at

Aytu BioPharma launches EXXUA depression drug nationwide

Tue, 20 Jan 2026 09:01:34 -0500

Aytu BioPharma Inc. (NASDAQ: AYTU) announced the nationwide commercial launch of EXXUA (gepirone), a depression medication that received FDA approval for treating major depressive disorder in adults. The company completed its launch meeting and sales training preparations.

EXXUA represents the first selective 5-HT1A receptor agonist approved by the FDA for major depressive disorder treatment. The once-daily medication targets specific serotonin receptors while minimizing activity at receptors linked to sexual dysfunction and weight gain, which are common side effects of traditional antidepressants.

According to the company, up to 70% of the 21 million Americans with major depressive disorder experience sexual dysfunction from current

Aytu BioPharma Highlights Opportunity for EXXUATM (gepirone) as New Way to Treat Major Depressive Disorder That Avoids Common Side Effects of Sexual Dysfunction and Significant Weight Gain following l

Tue, 20 Jan 2026 09:00:00 -0500

EXXUA addresses frequent causes of treatment discontinuation with first-line SSRIs and SNRIs

Now commercially available through retail pharmacies and participating Aytu RxConnect^® pharmacies to support patient access

DENVER, COLORADO / ACCESS Newswire / January 20, 2026 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on advancing innovative medicines to treat complex central nervous system disorders and improve the quality of life of patients, today announced the nationwide commercial launch of EXXUA and successful completion of its launch meeting last week that finalized sales training and launch preparations for EXXUA,

Aytu BioPharma Highlights Opportunity for EXXUATM (gepirone) as New Way to Treat Major Depressive Disorder That Avoids Common Side Effects of Sexual Dysfunction and Significant Weight Gain following l

Tue, 20 Jan 2026 09:00:00 -0500

EXXUA addresses frequent causes of treatment discontinuation with first-line SSRIs and SNRIs

Now commercially available through retail pharmacies and participating Aytu RxConnect^® pharmacies to support patient access

DENVER, COLORADO / ACCESS Newswire / January 20, 2026 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on advancing innovative medicines to treat complex central nervous system disorders and improve the quality of life of patients, today announced the nationwide commercial launch of EXXUA and successful completion of its launch meeting last week that finalized sales training and launch preparations for EXXUA,

Aytu BioPharma to Participate in the Lytham Partners 2026 Investor Healthcare Summit on January 15, 2026

Tue, 13 Jan 2026 16:15:00 -0500

DENVER, CO / ACCESS Newswire / January 13, 2026 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases to improve the quality of life for patients, announced today that Josh Disbrow, Chief Executive Officer of Aytu, will participate in a fireside chat moderated by Thomas Flaten, Senior Research Analyst at Lake Street Capital Markets, at the Lytham Partners 2026 Investor Healthcare Summit.

The webcast will take place at 5:00 p.m. Eastern time on Thursday, January 15, 2026. The webcast

Aytu BioPharma to Participate in the Lytham Partners 2026 Investor Healthcare Summit on January 15, 2026

Tue, 13 Jan 2026 16:15:00 -0500

The webcast will take place at 5:00 p.m. Eastern time on Thursday, January 15, 2026. The webcast

Aytu BioPharma Details Agenda for Investor Day Scheduled for January 20, 2026 in New York City

Mon, 12 Jan 2026 08:00:00 -0500

DENVER, CO / ACCESS Newswire / January 12, 2026 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases to improve the quality of life for patients, today provided additional details for its upcoming Investor Day, scheduled for Tuesday, January 20, 2026, at 11:00 a.m. Eastern time in New York City. The Investor Day will be both in-person and available to view via webcast.

In-Person Information

Convene Conference Center
530 Fifth Avenue
New York, NY 10036

Advance registration is required for in-person attendance. Please

Aytu BioPharma Details Agenda for Investor Day Scheduled for January 20, 2026 in New York City

Mon, 12 Jan 2026 08:00:00 -0500

In-Person Information

Convene Conference Center
530 Fifth Avenue
New York, NY 10036

Advance registration is required for in-person attendance. Please

Aytu BioPharma to Host Investor Day on January 20, 2026 in New York City

Thu, 18 Dec 2025 09:00:00 -0500

DENVER, CO / ACCESS Newswire / December 18, 2025 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases to improve the quality of life for patients, will be hosting an Investor Day on Tuesday, January 20, 2026, at 11:00 a.m. Eastern time in New York City.

The Investor Day will include presentations from Aytu's senior leadership and discussions with Key Opinion Leaders ("KOLs") regarding the EXXUA™ (gepirone) extended-release tablets ("EXXUA") opportunity, followed by a live Q&A session. EXXUA is